Alzchem Group Ag · XETR:ACT
Alzchem — Q1 2026 Earnings Presentation
32 slides from Alzchem's earnings presentation, Apr 30, 2026
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Q1 2026 Analyst Presentation, April 30, 2026
Q1 ANDREAS NIEDERMAIER, CEO ANDREAS LÖSLER , CFO 2026 April 30, 2026
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available
Slide 4: Agenda – Analyst Presentation Q1 2026
AGENDA – ANALYST PRESENTATION Q1 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 5: Highlights
HIGHLIGHTS Positive start into the new year – all expectations met Strong performance of previous year was Free float increased to nearly 75% surpassed once again: leading to higher stock trading volumes + 3% revenue growth + 18% EBITDA growth ✓ Carbide furnace overhaul on schedule Ingredients in sp
Slide 6: Projects - Update
PROJECTS - UPDATE All Projects are essentially in line with expectations Update on expansion projects Nitroguanidine 1: ✓ Final construction activities in Germany; first test runs have begun ✓ Nitroguanidine 2: US site search nearly finalized; Initial facility planning activities have already commen
Slide 7: Agenda – Analyst Presentation Q1 2026
AGENDA – ANALYST PRESENTATION Q1 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 8: Basics & Intermediates
BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.
Slide 9: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Sales and EBITDA reductions on expected level SALES SALES EBITDA SALES ANALYSIS - 14.0% 49.3 43.3 DELTA DELTA 41.8 40.9 41.9 42.6 35.6 36.7 Q1 01 - 03 33.5 - 14.0% Volume - 13.7% - 13.7% 42.6 Price - 0.1% - 0.1% 36.7 Currency - 0.2% - 0.2% Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 10: Specialty Chemicals
SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high - quality specialty chemical ingredients with strong growth perspectives.
Slide 11: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in M€) Strong growth is supported by increased volumes and price increases SALES +11.4% SALES EBITDA SALES ANALYSIS 100.1 105.3 DELTA 93.0 94.5 97.2 DELTA 85.8 89.0 87.0 Q1 80.4 +11.4% 01 - 03 Volume + 6.4% + 6.4% 105.3 Price + 8.4% + 8.4% 94.5 Currency - 3.3% - 3.3% Q1
Slide 12: Other & Holding
OTHER & HOLDING The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.
Slide 13: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in M€) Regulated grid fees impact sales and result SALES SALES EBITDA COMMENTS - 11.2% 7.8 8.5 7.7 8.1 • Slight reduction in sales development 7.5 7.1 7.0 6.6 6.7 compared to the previous year - 11.2% 7.5 • Sales & EBITDA development mainly resulting from reduced grid fee ch
Slide 14: Financial Overview
FINANCIAL OVERVIEW All KPI above prior year – net income follows EBITDA growth Q1 Q1 2025 2026 Alzchem Group qoq % SALES yoy % DELTA DELTA 2025 2026 1-3 1-3 ANALYSIS Q1 01 - 03 SALES (in M€) 144.7 148.7 +2.7% 144.7 Volume148.7 +2.7% -0,6% -0,6% EBITDA (in M€) 27.4 32.3 +18.0% 27.4 Price 32.3 +5,6% +
Slide 15: Balance Sheet & Cashflow
BALANCE SHEET & CASHFLOW Free Cashflow influenced by investments and customer grants COMMENTS Balance sheet KPIs (T€) 31.12.2025 31.03.2026 Deviation • Increase in balance sheet tota l resulting from increased CAPEX Balance sheet total 617,679 654,476 36,797 6.0% Inventories 116,004 122,576 6,572 5.
Slide 16: Outlook 2026 (in M€)
OUTLOOK 2026 (in M€) Ongoing growth in sales and EBITDA despite high investments COMMENTS SALES EBITDA growth Outlook for 2026 confirmed to approx. 600 .0 M € Major assumptions are still valid growth • No significant impact of the Iran conflict; long - term disruption +7% to approx. of global supply
Slide 17: Financial Calendar
FINANCIAL CALENDAR Upcoming dates * MAY 5 2026 Annual General Meeting 2026 MAY 20 - 21 2026 Berenberg European Conference, Manhattan MAY 27 2026 Kepler Cheuvreux Virtual SMID CEO - CFO Week, Virtual JUL 30 2026 Half - year Financial Report 2026 Berenberg Food Ingredients & Chemicals Conference, SEP
Slide 18: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content ? WE APPRECIATE YOUR FEEDBACK! Link QR - Code 18
Slide 19: Investor Relations
Investor Relations T +49 8621 86 - 2888 F +49 8621 86 - 502888 AGILE SCIENCE ir@alzchem.com PURE RESULTS www.alzchem.com
Slide 20: Agenda – Analyst Presentation Q1 2026
AGENDA – ANALYST PRESENTATION Q1 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 21: KPI Impact of Customer Grants
KPI IMPACT OF CUSTOMER GRANTS Timing and effects on balance sheet and P&L EST KEY EFFECTS 1 KPI EFFECTS KPI EFFECTS 2025/2026 2027 et seq. Cash / Assets ↑ Cash / Assets → receivables liabilities Other receivables ↑ Other receivables ↓ contract liablities Equity → Equity ↑ other receiveables Contract
Slide 22: Balance Sheet
BALANCE SHEET Alzchem Group ALZCHEM GROUP (IN T€) 31.12.2025 31.03.2026 Deviation ALZCHEM GROUP (IN T€) 31.12.2025 31.03.2026 Deviation Share capital 101,763 101,763 Intangible assets 3,530 3,849 319 9.0% RETAINED EARNINGS (+) / LOSS (-) 232,111 250,069 17,958 7.7% Tangible assets 276,980 299,002 22
Slide 23: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M €) - 1.3% 88.2 87.1 79.7 +0.1 +0.9 - 0.8 - 1.3 - 7.4 IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION COSTS COSTS PAYMENTS REMEASURE - PROVISION TAX ASSETS LIABILITY 31.12.2025 EBITDA MENTS 31.03.2026 31
Slide 24: Income Statement
INCOME STATEMENT Alzchem Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ALZCHEM GROUP (IN T€) Deviation (Q1) 2025 2025 2025 2025 2026 2026 2026 2026 Revenue 144,680 142,879 137,266 137,290 148,653 3,973 3% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 11,436 3,433 624 545 4,143 -7
Slide 25: Income Statement
INCOME STATEMENT Alzchem Group Q1 Q1 YTD YTD ALZCHEM GROUP (IN T€) Deviation (QoQ) Deviation (YoY) 2025 2026 Mrz.2025 Mrz.2026 Revenue 144,680 148,653 3,973 2.7% 144,680 148,653 3,973 2.7% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 11,436 4,143 -7,294 -63.8% 11
Slide 26: Cashflow Statement
CASHFLOW STATEMENT Alzchem Group 1-3 1-3 CASHFLOW (IN M€) 2025 2026 Consolidated earnings before taxes 20,243 24,637 Depreciation on fixed and intangible assets 6,552 6,701 Decrease in pension provisions -768 -832 Loss (+) / Profit (-) from the sale of non-current assets 22 -27 Other non-cash income
Slide 27: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER Alzchem Group SALES 2024 2025 2026 YTD Q1 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Deviation PY (Q1) PY Actual Deviation PY (YOY) SALES T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ % T€ T€ T€ % Basics & Intermediates 49,299 41,848 40,927 41,929 42,638 35,605 43,309 33,539 36,66
Slide 28: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies BERLIN (GER) SUNDSVALL (SE) COVENTRY (UK) TROSTBERG (GER) SCHALCHEN (GER) HART a. d. ALZ (GER) WALDKRAIBURG (GER) © Alzchem Group AG / April 2026 SHANGHAI (CN) ATLANTA (USA) Production facilities in Germany (4) and Sweden (1) SALES COMPANY
Slide 29: “Verbund” – Fully Integrated Business Model
“VERBUND” – FULLY INTEGRATED BUSINESS MODEL Vertically integrated production of chemical products based on the NCN chain Segment Specialty Chemicals BENEFITS OF “VERBUND” Segment Basics & Inter - • Full control of product quality and specifications mediates • Lower costs • Higher financial predictab
Slide 30: Our Products and Markets
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS A nutritional additive for poultry and pigs Feed additive Creapure ® , premium brand for creatine monohydrate as ingredient in sports & health nutrition Food supplements Die
Slide 31: Our Products and Markets
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS Calcium carbide - based mixtures for hot metal desulphurization Steel industry Fuel for airbags. key production of the intermediate product Automotive INTERMEDIATES Pharmace
Slide 32: Key Share Data
KEY SHARE DATA Share details as of April 29, 2026 SHAREHOLDER SHARES OUTSTANDING 10,176,335 STRUCTURE four two na GmbH 10.14% LAST CLOSING PRICE EUR 174.30 Staluna Trade a. s. MARKET CAPITALIZATION EUR 1,774 m 9.20% TICKER ACT Löw SE 6.39% WKN A2YNT3 ISIN DE000A2YNT30 Frankfurt Stock Exchange – © Al